Unknown

Dataset Information

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.


ABSTRACT:

Background

The mechanism of action of oral cladribine, recently licensed for relapsing multiple sclerosis, is unknown.

Objective

To determine whether cladribine depletes memory B cells consistent with our recent hypothesis that effective, disease-modifying treatments act by physical/functional depletion of memory B cells.

Methods

A cross-sectional study examined 40 people with multiple sclerosis at the end of the first cycle of alemtuzumab or injectable cladribine. The relative proportions and absolute numbers of peripheral blood B lymphocyte subsets were measured using flow cytometry. Cell-subtype expression of genes involved in cladribine metabolism was examined from data in public repositories.

Results

Cladribine markedly depleted class-switched and unswitch

SUBMITTER: Ceronie B 

PROVIDER: S-EPMC5937883 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature